




已阅读5页,还剩94页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1,Laboratory Diagnosis,2,Category of Sample,Blood, Urine, Stool, nasal washing, nasal swab , throat swab, saliva , sputum, rectal swab, vesicle fluid( scraping or swab), tissue ,brain biopsy, cerebrospinal fluid, et al.,3,Laboratory Diagnosis,Microscopy IdentificationVirus isolation and identificationDetection of viral proteins( antigens and enzymes)Detection of viral genetic material Serologic procedures,4,Microscopy Identification,Light microscopyFluorescent microscopyElectron microscopy,5,Light microscopy,Characteristic CPE Inclusion Bodies,6,Cell deathCell roundingDegenerationAggregationLoss of attachments to substrateCharacteristic histological changes:inclusion bodies in the nucleus or cytoplasm, margination of chromatinSyncytia: multinucleated giant cells caused by virus-induced cell-cell fusion,7,Fluorescent microscopy,Fluorescent-antibody staining,8,Electron microscopy,Direct detection : Human rotavirus; HAV; HBV; Smallpox virus; Herpes virus.Immune Electron microscopy: Human rotavirus; HAV;,9,Laboratory Diagnosis,Microscopy IdentificationVirus isolation and identificationDetection of viral proteins( antigens and enzymes)Detection of viral genetic material Serologic procedures,10,Viral isolation and Identification,Viral Growth and Cell culture Viral Detection Viral Identification Interpretation of culture results,11,Systems for the Propagation of Viruses,PeopleAnimals: cows, chickens, mice,rats, suckling mice Embryonated eggs Organ and tissue cultureOrgan culturePrimary tissue cultureCell lines: diploidTumor or (immortalized )cell line,12,Viral detection,CPEHemadsorptionInterfereMetabolize of cell,13,TCID50(Tissue culture infective dose),TCID50 is defined as that dilution of virus which will cause CPE in 50% of a given batch of cell cultureTCID50= log10 of highest dilution giving 100%CPE +1/2 (total number of test units showing CPE)/ (number of test units per dilution),14,Viral identification,Complement fixation: Hemagglutination inhibitionNeutralizationImmunofluorescence ( direct or indirect)Latex agglutination In situ EIA ELISARIA(radioimmuno,15,Laboratory Diagnosis,Microscopy IdentificationVirus isolation and identificationDetection of viral proteins( antigens and enzymes)Detection of viral genetic material Serologic procedures,16,Detection of viral proteins( antigens and enzymes),Antigen detection ( ELISA, RIA, Western blot)Hemagglutination and hemadsorptionEnzyme activities( reverse transcriptase)Protein patterns( electrophoresis ),17,Laboratory Diagnosis,Microscopy IdentificationVirus isolation and identificationDetection of viral proteins( antigens and enzymes)Detection of viral genetic material Serologic procedures,18,Detection of viral genetic material,PCR ( Polymerase chain reaction)RT-PCR (Reverse transcriptase polymerase chain reaction)Southern(DNA), Northern(RNA), and dot blots DNA genome hybridization in situ(cytochemistry)Electrophoretic mobilities of RNA for segmented RNA viruses( Electrophoresis) Restriction endonuclease cleavage patterns,19,Laboratory Diagnosis,Microscopy IdentificationVirus isolation and identificationDetection of viral proteins( antigens and enzymes)Detection of viral genetic material Serologic procedures,20,Serologic procedures,If the antibody titer in the convalesent-phase serum sample is at least 4-fold higher than the titer in the acute-phase serum sample, the patient is considered to be infected.In certain viral diseases, the presence of IgM antibody is used to diagnose current infectionOther nonspecific serologic tests are available,21,Serologic procedures,Complement fixation: Hemagglutination inhibitionNeutralizationImmunofluorescence ( direct or indirect)Latex agglutination In situ EIA ELISARIA,22,Viruses Diagnosed by Serology,Epstein-Barr virusRubella virusHepatitis A, B, C, D, and E virusesHIVHuman T-cell Leukemia virusArboviruses ( Encephalitis viruses),23,Prevention,Successes of the Past Possibilities for the Future,24,Active immunization,Vaccines,25,Overview of Active immunization,Active immunization - administration of antigen resulting in production of a specific immune response with immunologic memory. Response may be cellular or humoral or both. Natural immunity - to diseases you have caught and successfully fought Artificial immunity Vaccination(vaccines),26,Attributes of a good vaccine,Ability to elicit the appropriate immune response for the particular pathogenLong term protection ideally life-longSafety vaccine itself should not cause disease Stable retain immunogenicity, despite adverse storage conditions prior to administrationIn-expensive,27,LIVE VACCINES,Live attenuated organismHeterologous vaccinesLive recombinant vaccines Attributes live vaccines,28,Live attenuated organism,Organisms whose virulence has been artificially reduced by in vitro Culture under adverse conditions, such as reduced temperature.,29,Heterologous vaccines,Closely related organism of lesser virulence, which shares many antigens with the virulent organism. The vaccine strain replication in the host and induces an immune response that cross reacts with antigens of the virulent organism.Vaccinia virus /cowpox virus- Variola virus,30,Live recombinant,Vector bovine vaccineBCG,31,Both cell mediated immunity and antibody responseActivates all phases of immune system. Can get humoral IgG and local IgARaises immune response to all protective antigens. Inactivation may alter antigenicity. More durable immunity; more cross-reactive Immunity is long livedSingle dose,Advantages of Attenuated Vaccines 2-1,32,Advantages of Attenuated Vaccines 2-2,Low cost Quick immunity in majority of vaccinees In case of polio and adeno vaccines, easy administration Easy transport in field Can lead to elimination of wild type virus from the community,33,Disadvantages of Live Attenuated Vaccine,Mutation; reversion to virulence (often frequent)Spread to contacts of vaccinee who have not consented to be vaccinated (could also be an advantage in communities where vaccination is not 100%) Spread vaccine not standardized-may be back-mutated Poor take in tropics Problem in immunodeficiency disease (may spread to these patients),34,Killed vaccines,The organism is propagated in bulk, in vitro, and inactivated with either beta-propiolactone or formaldehyde. These vaccines are not infectious and are therefore relatively safe. However, they are usually of lower immunogenicity and multiple doses may be needed to induce immunity. In addition, they are usually expensive to prepare.,35,Killed vaccines,Inactivated organism: rabies virus; epidmic type B encephalitis virus.Subunit Vaccines: Influenza virus( HA and NA)Recombinant proteins: HBV,36,Advantages of inactivated vaccines,Gives sufficient humoral immunity if boosters given No mutation or reversion Can be used with immuno-deficient patients These vaccines tend to be able to withstand more adverse storage conditions,Sometimes better in tropics,37,Disadvantages of inactivated vaccines,Many vaccinees do not raise immunitypoor, only antibody, no cell immediated immune responseresponse is short-lived and multiple doses are neededNo local immunity (important)Inactivated, therefore can not replicate in the host and cause diseaseFailure in inactivation and immunization with virulent virusExpense: Expensive to prepare,38,New Methods,Selection of attenuated virus strain Varicella Hepatitis AUse monoclonal antibodies to select for virus with altered surface receptor Rabies ReoUse mutagen and grow virus at 32 degrees. Selects for temperature-sensitive virus. Grows in upper respiratory tract but not lower flu (new vaccine) respiratory syncytial virus,39,New Methods,Passage progressively at cold temperaturesTS mutant in internal proteinsCan be re-assorted to so that coat is the strain that is this years flu strain,40,41,New Methods,Deletion mutants Suppression unlikely (but caution in HIV) Viable but growth restrictionsProblems Oncogenicity in some cases (adeno, retro),42,New Methods,43,Single gene (subunit) - problems,Surface glycoprotein poorly soluble - deletion? Poorly immunogenic Post-translational modifications Poor CTL response,44,Single gene (subunit) in expression vector,Vaccinate with live virusCanary Pox Infects human cells but does not replicate Better presentation CTL responseVacciniaAttenuated PolioBeing developed for anti-HIV vaccine,45,New Methods,Chemically synthesized peptide malariapoorly immunogenic,46,New methods,Anti-idiotype vaccine,epitope,Antibody with epitope binding site,Virus,47,Anti-idiotype vaccine cont,Make antibody against antibody idiotype,Anti-idiotype antibody mimics the epitope,48,Anti-idiotype antibody cont 2,Use anti-idiotype antibody as injectable vaccine,Antibody to anti-idiotype antibody,Binds and neutralizes virus,Use as vaccine,49,New Methods,New “Jennerian Vaccines” Live vaccines derived from animal strains of similar viruses Naturally attenuated for humansRotavirus: Monkey Rota80% effective in some human populationsIneffective in othersDue to differences in circulating viral serotypes,50,New Methods,New Jennerian VaccinesBovine parainfluenza Type 3Bovine virus is: Infectious to humans Immunogenic (61% of children get good response) Poorly transmissablePhenotypicaly stable,51,New Methods,52,Vaccines,1796 Jenner: wild type animal-adapted virus 1800s Pasteur: Attenuated virus 1996 DNA vaccinesThe third vaccine revolution,53,DNA vaccines,DNA vaccines are at present experimental , but hold promise for future therapy since they evoke both humoral and cell-mediated immunity, without the dangers associated with live virus vaccines,54,DNA Vaccines,plasmid,Muscle cell,Gene for antigen,Muscle cell expresses protein - antibody madeCTL response,55,DNA Vaccines,Plasmids are easily manufactured in large amounts DNA is very stable DNA resists temperature extremes so storage and transport are straight forward DNA sequence can be changed easily in the laboratory. This means that we can respond to changes in the infectious agent By using the plasmid in the vaccinee to code for antigen synthesis, the antigenic protein(s) that are produced are processed (post-translationally modified) in the same way as the proteins of the virus against which protection is to be produced. This makes a far better antigen than purifying that protein and using it as an immunogen.,56,DNA Vaccines,Mixtures of plasmids could be used that encode many protein fragments from a virus/viruses so that a broad spectrum vaccine could be produced The plasmid does not replicate and encodes only the proteins of interest No protein component so there will be no immune response against the vector itself Because of the way the antigen is presented, there is a CTL response that may be directed against any antigen in the pathogen. A CTL response also offers protection against diseases caused by certain obligate intracellular pathogens (e.g. Mycobacterium tuberculosis),57,DNA Vaccines,Possible Problems Potential integration of plasmid into host genome leading to insertional mutagenesis Induction of autoimmune responses (e.g. pathogenic anti-DNA antibodies) Induction of immunologic tolerance (e.g. where the expression of the antigen in the host may lead to specific non-responsiveness to that antigen),58,DNA Vaccines,DNA vaccines produce a situation that reproduces a virally-infected cellGives: Broad based immune response Long lasting CTL response Advantage of new DNA vaccine for flu:CTL response can be against internal proteinIn mice a nucleoprotein DNA vaccine is effective against a range of viruses with different hemagglutinins,59,Adjuvants,Certain substances, when administered simultaneously with a specific antigen, will enhance the immune response to that antigen.,60,Adjuvants in common use,Aluminium saltsLiposomes and immunostimulating complexesComplet Freunds adjuvant is an emulsion of mycobacteria, oil and waterIncomplete Freunds adjuvantMuramyl di-peptideCytokines,61,Possible action modes of adjuvant,By trapping antigen in the tissues, thus allowing maximal exposure to dendritic cells and specific T and B lymphocytesBy activating antigen-presenting cells to secrete cytokines that enhance the recruitment of antigen-specific T and B cells to the site of inoculation,62,Smallpox,63,Smallpox,Variolation1% v. 25% mortalityLife-long immunity No drift or shift,64,Smallpox,Vaccination Jenner 1796 : Cowpox/Swinepox 1800s Compulsory childhood vaccination 1930s Last natural UK case 1940s last natural US case 1958 WHO program October 1977: Last case (Somalia),65,Smallpox,No animal reservoir Lifelong immunity Subclinical cases rare Infectivity does not precede overt symptoms One Variola serotype Effective vaccine Major commitment by governments,66,polio,Killed virus vaccine(Salk, 1954)Live attenuated oral polio vaccine( Sabin, 1957)The inactivated Salk vaccines is recommended for children who are immunosuppressed.,67,Polio Vaccine,68,Reported cases per 100000 population,100,10,1,0.1,0.001,0.01,1950,1960,1970,1980,1990,Inactivated (Salk) vaccine,Oral vaccine,Cases per 100,000 population United States,69,10000,1000,100,10,1,0,Reported cases,1950,1955,1960,1965,1970,1975,Killed (Salk) vaccine,Total casesSweden and Finland,70,71,Sabin Polio Vaccine,Attenuation by passage in foreign hostMore suited to foreign environment and less suited to original hostGrows less well in original hostPolio: Monkey kidney cells Grows in epithelial cells Does not grow in nerves No paralysis Local gut immunity (IgA)Pasteur rabies vaccine also attenuated,72,Salk Polio Vaccine,Formaldehyde-fixed No reversion,73,Polio Vaccine,Why use the Sabin vaccine?: Local immunity: Vaccine virus just like natural infection Stopping replication in G.I. Tract stops viral replication TOTALLY Dead Salk vaccine virus has no effect on gut replication No problem with selective inactivation Greater cross reaction as vaccine virus also has antigenic drift Life-long immunity,74,Measles,Live attenuated virus grown in chick embryo fibroblasts, first introduced in the 1960s.Etiology: Measles virus Incubation: 8 to 12 days Clinical Manifestations: cough, coryza, conjunctivitis , erythematous maculopapular rash fever ,Koplik Spots ,complictions include Encephalitis, Pneumonia, and SSPE Treatment: Supportive,75,Mumps,Live attenuated virus developed in the 1960sMMR vaccineEtiology: Mumps Virus Incubation: 16 to 18 days Clinical Manifestations: swelling of the salivary glands complications include Meningitis, Orchitis, Encephalitis, and Deafness,76,rubella,Live attenuated virusEtiology: Rubella Virus Incubation: 14 to 21 days Clinical Manifestations: Congenital , cataracts patent ductus arteriosus , deafness mental retardation , Postnatal mild disease , erythematous maculopapular rash , postauricular lymphadenopathy transient polyarthralgias,77,Hepatitis B,Two vaccines are in current use:A serum derived vaccineA recombinant vaccineEtiology: Hepatitis B Virus Incubation: 120 days (average) Clinical Manifestations: jaundice ; anorexia nausea and vomiting ; malaise complications include the development of a chronic carrier state with a high risk for Hepatocellular Carcinoma (liver cancer),78,Hepatitis A,Formalin-inactivated , cell cultured-derived virus,79,Yellow fever,The 17D strain is a live attenuated vaccine developed in 1937.It is a highly effective vaccine which is administered to residents in the tropics and travellers to endemic areas.,80,Rabies,No safe attenuated strain of rabies virus has yet been developed for human. Vaccines in current use include: a The neurotissue vaccine b human diploid cell culture-derived vaccine, which is much safer.There are two situation where vaccine is given: a Post-exposure prophylaxis, followinf the bite of a rabid animal, Hyperimmune rabies globulin may also administered . b Pro-exposure prophylaxis is used for protection of those occupation puts them at risk of infection with rabies.,81,Influenza,New vaccines are produced every year,82,Varicella-Zoster virus,Not licensed vaccines,83,84,Passive Immunisation,85,Modes of immunization,Passive immunization - administration of antibody-containing serum to provide immediate, but temporary protection. Doesnt activate a lasting specific immune response.,86,Natural,Provides immunity for diphtheria, tetanus, streptococcus, rubeola (red measles), rubella (German measles), mumps, polio, and others.,87,Artificial,Often used as antitoxins for things such as black widow spider and snake bites, botulism, and tetanus. Important for some infectious diseases such as rabies, since it provides immediate protection rather than waiting the 7-10 days for a protective response to develop from active immunization.,88,Immunoglobulin,“Normal”Immune globulinHyper-immune globulin,89,“Normal”Immune globulin,Low titres of antibody to a wide range of human virusesHepatitis A virus infectionParvovirus infectionEnterovirus infections (in neonates)HIV-infected babies,90,Hyper-immune globulin- high titres of antibody to particular viruses,Zoster immune globulin:
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 房产交易合同智能审核系统企业制定与实施新质生产力项目商业计划书
- 新媒体资源整合营销企业制定与实施新质生产力项目商业计划书
- 2025年低碳城市规划与城市交通系统优化案例分析
- 2025年创新药物研发靶点筛选与验证技术市场动态报告
- 2025年传统食品工业化生产智能化改造案例分析报告
- 2025年传统工业制造行业工业自动化设备市场潜力分析报告
- 2025年储能行业多元化市场投资机会与风险评估报告
- 儿科护理学:儿童的生长与发育
- 2025年储能技术多元化在电网储能系统稳定性与可靠性分析报告
- 地铁车辆检修工练习测试题附答案
- 2024年山东省青岛市中考语文试卷(含答案解析)
- 八年级语文下册综合性学习之以和为贵
- 2024年广东省广州市花都区五年级数学第二学期期末学业水平测试试题含解析
- 北京市西城区三帆中学2023-2024学年七年级下学期期中数学试题(无答案)
- 《学会专注高效学习》初中主题班会课件
- (2024年)发生输液反应时应急预案及处理流程
- SA8000:2014社会责任-中文
- 四年级如何进行有效期末复习课件
- 北京开放大学《集装箱班轮运输业务与法律》终结性考试复习题库(附答案)
- DB32/T 4700-2024 蓄热式焚烧炉系统安全技术要求
- 肿瘤医院推广方案
评论
0/150
提交评论